OZAN CEMAL IÇAÇAN1, OSMAN YOKUŞ2, FETTAH SAMETOĞLU3, HABIP GEDIK4
1Internal Diseases Physician, Department of Internal Diseases, Ministry of Health Istanbul Training and Research Hospital, İstanbul, Turkey - 2Hematology and Internal Diseases Physician, Department of Hematology, Ministry of Health Istanbul Training and Research Hospital, İstanbul, Turkey - 3Internal Diseases Physician, Department of Internal Diseases, Ministry of Health Istanbul Training and Research Hospital, İstanbul, Turkey - 4Infectious Diseases and Clinical Microbiology Physician, Department of Infectious Diseases and Clinical Microbiology, Ministry of Health Bakirköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey
Objective: It was aimed to investigate the serum vitamin D (Vit D) levels of acute leukemia cases and compare their levels with those of healthy people to evaluate the relationship between acute leukemia and serum Vit D level.
Material and method: In this retrospective, case-control study, the vitamin levels of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) patients who were followed-up and treated between 2012 and 2016 at the hematology clinic of Ministry of Health Istanbul Training and Research Hospital were evaluated in order to compare with the vit D levels of healthy individuals who were taken as control group in the same period.
Results: In the study, 29 patients with AML, 17 patients with ALL and 50 healthy controls were included. There was a statis- tically significant difference between Vit D levels of patients group and control group (p= 0.001). The Vit D level of control group was statistically higher than those of ALL and AML patients. (p = 0.005; p = 0.001, respectively). In the subgroup analysis, there was a significant difference between Vit D levels of both ALL (p = 0.005) and AML (p: 0.001) patient groups and Vit D levels of control group. However, there was no statistical significance between Vit D levels of AML and ALL patients (p = 0.524).
Conclusion: Vit D levels of patients with acute leukemia were found to be lower than those of healthy controls. In case patients with hematological malignancy have Vit D deficit, especially in the case of serious deficiencies, the replacement therapy should be administered. Prospective randomized controlled trials on multiple cases of acute leukemia are needed to clarify the effects of Vit D deficiency on disease progression and survival.
Vitamin D, acute leukemia, acute myeloid leukemia, acute lymphoblastic leukemia, body-mass index.